EUCTR2020-001492-33-FR进行中（未招募）1 期
Interest in the administration of Dornase alpha aerosol in ARDS secondary to respiratory infection by the coronavirus SRASCoV-2 / COVID-19 - COVID19-COVIDornase
Hôpital Fondation Adolphe de Rothschild0 个研究点目标入组 100 人开始时间: 2020年4月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Major patient (age = 18 years old);
- •- Hospitalized in intensive care;
- •- Severe pneumonia COVID-19 with Berlin criteria for ARDS (PaO2/FiO2<300 and PEP>5).
- •- Intubated for less than 8 days ;
- •- Expected duration of mechanical ventilation is >48 hours;
- •- Carrying an arterial catheter;
- •- Affiliated with or beneficiary of a health insurance social protection scheme
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •- Known hypersensitivity to Dornase alfa or any of the excipients;
- •- Pregnant or nursing woman;
- •- Patient with legal pro
研究者
相似试验
已完成
4 期
Is Dornase alfa (Pulmozyme ) effective if administered at night, in relation to airways clearance techniques? A multi centre, crossover, randomised controlled trial for people with cystic fibrosis.Cystic Fibrosis (CF)Human Genetics and Inherited Disorders - Cystic fibrosisACTRN12607000155493Royal Children's Hospital46
进行中（未招募）
1 期
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant HypertensionA Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects with Resistant Hypertension Receiving Combination Therapy with Three or MoreAntihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine or Placebo - DORADO-ACMedDRA version: 8.1Level: LLTClassification code 10038274Term: Refractory hypertensionResistant hypertensionEUCTR2006-003547-23-DKGilead Sciences, Inc.770
进行中（未招募）
1 期
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant HypertensionA Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects with Resistant Hypertension Receiving Combination Therapy with Three or MoreAntihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine or Placebo - DORADO-ACResistant hypertensionEUCTR2006-003547-23-CZGilead Sciences, Inc.770
进行中（未招募）
不适用
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant HypertensionA Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects with Resistant Hypertension Receiving Combination Therapy with Three or MoreAntihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine or Placebo - DORADO-ACResistant hypertensionEUCTR2006-003547-23-DEGilead Sciences, Inc.770
进行中（未招募）
不适用
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant HypertensionA Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects with Resistant Hypertension Receiving Combination Therapy with Three or MoreAntihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine or Placebo - DORADO-ACMedDRA version: 8.1Level: LLTClassification code 10038274Term: Refractory hypertensionResistant hypertensionEUCTR2006-003547-23-BEGilead Sciences, Inc.770